{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:25:26Z","timestamp":1740108326677,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Heart Foundation of Northern Sweden"},{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess a systematic implementation approach for introducing dapagliflozin to individuals with heart failure and reduced ejection fraction in an outpatient clinical setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective medical record data were analysed. All individuals diagnosed with heart failure who resided within the hospital catchment area and had visited cardiology or internal medicine department between 2010 and 2019 were screened by using the main inclusion criteria from the DAPA-HF trial. The effectiveness of the previously described seven-step systematic implementation approach was assessed by the proportion receiving information letter, dapagliflozin treatment, follow-ups at 2\u201312 weeks and 12 months post-dapagliflozin initiation, persistence on dapagliflozin, adverse events, and reasons for discontinuation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 2433 individuals, 352 met the main DAPA-HF trial criteria in step 2. After exclusions in steps 3 and 4, 191 individuals remained. Of these, 158 were invited for eligibility discussion in step 5, with 107 having received an information letter beforehand. In step 6, dapagliflozin was prescribed to 69 individuals, and in step 7, follow-ups were conducted with 56 individuals at 2\u201312 weeks and 62 individuals at 12 months. Sixty out of 69 persisted on dapagliflozin after 12 months. Adverse events were reported by nine individuals. Discontinuation was attributed to reasons such as urinary tract infections, genital or abdominal discomfort, and hypotension.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The systematic introduction of dapagliflozin to heart failure patients was effective. Despite this, challenges in uniformly implementing procedures across patients were evident, emphasizing the necessity for a systematic implementation approach.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-024-03707-4","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T14:02:15Z","timestamp":1718028135000},"page":"1363-1371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of a systematic approach for implementing novel medications in clinical practice: an observational study with dapagliflozin"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6785-2895","authenticated-orcid":false,"given":"Helena","family":"Norberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-8411","authenticated-orcid":false,"given":"Therese","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-178X","authenticated-orcid":false,"given":"Erik","family":"H\u00e5kansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-6121","authenticated-orcid":false,"given":"Karin Hellstr\u00f6m","family":"\u00c4ngerud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-7791","authenticated-orcid":false,"given":"Krister","family":"Lindmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"3707_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fpubh.2018.00328","volume":"6","author":"B Godman","year":"2018","unstructured":"Godman B, Bucsics A, Vella Bonanno P et al (2018) Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health 6:328. https:\/\/doi.org\/10.3389\/fpubh.2018.00328","journal-title":"Front Public Health"},{"key":"3707_CR2","doi-asserted-by":"publisher","DOI":"10.1787\/7a7afb35-en","volume-title":"Health at a glance 2023: OECD indicators","author":"OECD","year":"2023","unstructured":"OECD (2023) Health at a glance 2023: OECD indicators. https:\/\/doi.org\/10.1787\/7a7afb35-en"},{"key":"3707_CR3","unstructured":"The National Board of Health and Welfare (2023) Pharmaceutical sales in Sweden: analysis and forecast for 2023\u20132026. [L\u00e4kemedelsf\u00f6rs\u00e4ljning i Sverige \u2013 analys och prognos 2023\u20132026] [In Swedish]. https:\/\/www.socialstyrelsen.se\/globalassets\/sharepoint-dokument\/artikelkatalog\/ovrigt\/2023-6-8601.pdf"},{"key":"3707_CR4","unstructured":"Stockholm (2024) Region Stockholm. Janusinfo.se: National joint introduction [Internet].\u00a0https:\/\/janusinfo.se\/ntradet\/samverkanlakemedelstartsida\/processordnatinforande\/nationaljointintroduction.4.64582f2718842410f2e24805.html"},{"key":"3707_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010716-104952","volume":"57","author":"KL Lavoie","year":"2017","unstructured":"Lavoie KL, Rash JA, Campbell TS (2017) Changing provider behavior in the context of chronic disease management: focus on clinical inertia. Annu Rev Pharmacol Toxicol 57:263\u2013283. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-104952","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3707_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","volume":"5","author":"N Luo","year":"2017","unstructured":"Luo N, Fonarow GC, Lippmann SJ et al (2017) Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from get with the guidelines-heart failure (GWTG-HF). JACC Heart Fail 5:305\u2013309. https:\/\/doi.org\/10.1016\/j.jchf.2016.12.018","journal-title":"JACC Heart Fail"},{"key":"3707_CR7","doi-asserted-by":"publisher","first-page":"e004302","DOI":"10.1161\/circheartfailure.117.004302","volume":"11","author":"LR Sangaralingham","year":"2018","unstructured":"Sangaralingham LR, Sangaralingham SJ, Shah ND, Yao X, Dunlay SM (2018) Adoption of sacubitril\/valsartan for the management of patients with heart failure. Circ Heart Fail 11:e004302. https:\/\/doi.org\/10.1161\/circheartfailure.117.004302","journal-title":"Circ Heart Fail"},{"key":"3707_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12883","author":"M Fu","year":"2020","unstructured":"Fu M, Vedin O, Svennblad B et al (2020) Implementation of sacubitril\/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.12883. Online ahead of print","journal-title":"ESC Heart Fail"},{"key":"3707_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamacardio.2019.4982","volume":"5","author":"A Sumarsono","year":"2020","unstructured":"Sumarsono A, Vaduganathan M, Ajufo E et al (2020) Contemporary patterns of Medicare and Medicaid utilization and associated spending on Sacubitril\/Valsartan and Ivabradine in heart failure. JAMA Cardiol 5:336\u2013339. https:\/\/doi.org\/10.1001\/jamacardio.2019.4982","journal-title":"JAMA Cardiol"},{"key":"3707_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"key":"3707_CR11","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","volume":"20","author":"G Savarese","year":"2018","unstructured":"Savarese G, Carrero JJ, Pitt B et al (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart failure Registry. Eur J Heart Fail 20:1326\u20131334. https:\/\/doi.org\/10.1002\/ejhf.1182","journal-title":"Eur J Heart Fail"},{"key":"3707_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/heartjnl-2017-312720","volume":"104","author":"G Savarese","year":"2018","unstructured":"Savarese G, Sartipy U, Friberg L, Dahlstr\u00f6m U, Lund LH (2018) Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. Heart 104:1093\u20131100. https:\/\/doi.org\/10.1136\/heartjnl-2017-312720","journal-title":"Heart"},{"key":"3707_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ejhf.496","volume":"18","author":"T Thorvaldsen","year":"2016","unstructured":"Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH (2016) Use of evidence-based therapy and survival in heart failure in Sweden 2003\u20132012. Eur J Heart Fail 18:503\u2013511. https:\/\/doi.org\/10.1002\/ejhf.496","journal-title":"Eur J Heart Fail"},{"key":"3707_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/anec.12243","volume":"20","author":"R Hatala","year":"2015","unstructured":"Hatala R, Lunati M, Calvi V et al (2015) Clinical implementation of cardiac resynchronization therapy-regional disparities across selected ESC member countries. Ann Noninvasive Electrocardiol 20:43\u201352. https:\/\/doi.org\/10.1111\/anec.12243","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"3707_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00228-019-02782-2","volume":"76","author":"H Norberg","year":"2020","unstructured":"Norberg H, Pranic V, Bergdahl E, Lindmark K (2020) Differences in medical treatment and clinical characteristics between men and women with heart failure - a single-centre multivariable analysis. Eur J Clin Pharmacol 76:539\u2013546. https:\/\/doi.org\/10.1007\/s00228-019-02782-2","journal-title":"Eur J Clin Pharmacol"},{"key":"3707_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00228-020-02979-w","volume":"77","author":"H Norberg","year":"2021","unstructured":"Norberg H, Bergdahl E, \u00c4ngerud KH, Lindmark K (2021) A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study. Eur J Clin Pharmacol 77:125\u2013131. https:\/\/doi.org\/10.1007\/s00228-020-02979-w","journal-title":"Eur J Clin Pharmacol"},{"key":"3707_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ehf2.12251","volume":"5","author":"H Norberg","year":"2018","unstructured":"Norberg H, Bergdahl E, Lindmark K (2018) Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study. ESC Heart Fail 5:337\u2013343. https:\/\/doi.org\/10.1002\/ehf2.12251","journal-title":"ESC Heart Fail"},{"key":"3707_CR18","doi-asserted-by":"publisher","first-page":"1894155","DOI":"10.1155\/2021\/1894155","volume":"2021","author":"E H\u00e5kansson","year":"2021","unstructured":"H\u00e5kansson E, Norberg H, Sj\u00e4lander S, Lindmark K (2021) Eligibility of dapagliflozin and empagliflozin in a real-world heart failure population. Cardiovasc Ther 2021:1894155. https:\/\/doi.org\/10.1155\/2021\/1894155","journal-title":"Cardiovasc Ther"},{"key":"3707_CR19","doi-asserted-by":"publisher","first-page":"e065001","DOI":"10.1136\/bmjopen-2022-065001","volume":"12","author":"I Jern","year":"2022","unstructured":"Jern I, Forsell S, Norberg H (2022) Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study. BMJ Open 12:e065001. https:\/\/doi.org\/10.1136\/bmjopen-2022-065001","journal-title":"BMJ Open"},{"key":"3707_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"3707_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1515\/cclm-2013-0741","volume":"52","author":"U Nyman","year":"2014","unstructured":"Nyman U, Grubb A, Larsson A et al (2014) The revised Lund-Malm\u00f6 GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin Chem Lab Med 52:815\u2013824. https:\/\/doi.org\/10.1515\/cclm-2013-0741","journal-title":"Clin Chem Lab Med"},{"key":"3707_CR22","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/ehf2.12643","volume":"7","author":"A Jonsson","year":"2020","unstructured":"Jonsson A, Viklund I, Jonsson A et al (2020) Comparison of creatinine-based methods for estimating glomerular filtration rate in patients with heart failure. ESC Heart Fail 7:1150\u20131160. https:\/\/doi.org\/10.1002\/ehf2.12643","journal-title":"ESC Heart Fail"},{"key":"3707_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/14740338.2018.1428305","volume":"17","author":"A Consoli","year":"2018","unstructured":"Consoli A, Formoso G, Baldassarre MPA, Febo F (2018) A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf 17:293\u2013302. https:\/\/doi.org\/10.1080\/14740338.2018.1428305","journal-title":"Expert Opin Drug Saf"},{"key":"3707_CR24","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1080\/14656566.2021.1953471","volume":"22","author":"MK Nicholson","year":"2021","unstructured":"Nicholson MK, Ghazal Asswad R, Wilding JP (2021) Dapagliflozin for the treatment of type 2 diabetes mellitus - an update. Expert Opin Pharmacother 22:2303\u20132310. https:\/\/doi.org\/10.1080\/14656566.2021.1953471","journal-title":"Expert Opin Pharmacother"},{"key":"3707_CR25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/phar.2114","volume":"38","author":"M Livet","year":"2018","unstructured":"Livet M, Haines ST, Curran GM et al (2018) Implementation science to advance care delivery: a primer for pharmacists and other Health professionals. Pharmacotherapy 38:490\u2013502. https:\/\/doi.org\/10.1002\/phar.2114","journal-title":"Pharmacotherapy"},{"key":"3707_CR26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"3707_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/circulationaha.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ et al (2017) Lower risk of heart failure and death in patients initiated on sodium-glucose Cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose Cotransporter-2 inhibitors). Circulation 136:249\u2013259. https:\/\/doi.org\/10.1161\/circulationaha.117.029190","journal-title":"Circulation"},{"key":"3707_CR28","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1161\/circulationaha.117.031227","volume":"137","author":"JA Udell","year":"2018","unstructured":"Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N (2018) Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL Population-based Cohort Study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation 137:1450\u20131459. https:\/\/doi.org\/10.1161\/circulationaha.117.031227","journal-title":"Circulation"},{"key":"3707_CR29","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"PB Ryan","year":"2018","unstructured":"Ryan PB, Buse JB, Schuemie MJ et al (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 20:2585\u20132597. https:\/\/doi.org\/10.1111\/dom.13424","journal-title":"Diabetes Obes Metab"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03707-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03707-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03707-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:04:19Z","timestamp":1722927859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03707-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3707"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03707-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of pseudonymized patient data for the purpose of this study was approved by The Regional Ethical Review Board in Ume\u00e5 (registration number 2015-419-31), the Swedish Ethical Review Authority, Sweden, (registration number 2023-03695-01), and the Ume\u00e5 University Hospital. The study was carried out in accordance with the Declaration of Helsinki. Since the study was based on existing data retrospectively retrieved from medical records of routine care, ethical approval was granted without the requirement of patient consent. The research data is stored and handled in accordance with the Ume\u00e5 University data management principles.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors HN, EH, KH\u00c4, and KL have no relevant financial or non-financial interests to disclose. TA reports speaker honoraria from Astra Zeneca, Boerhinger Ingelheim, Pharmacosmos and Vifor Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}